The University of Southampton
University of Southampton Institutional Repository

Personalized medicine in interstitial lung diseases

Personalized medicine in interstitial lung diseases
Personalized medicine in interstitial lung diseases


Purpose of review: A number of recent studies have explored the possibility to apply personalized medicine to interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), the most common and deadly of the idiopathic interstitial pneumonias. In our review, we summarize and discuss the most recent literature on personalized medicine in IPF as well as hypersensitivity pneumonitis and sarcoidosis, with emphasis on patient subgroups for which a personalized approach to disease prognostication and management may become a reality in the near future.

Recent findings: Most of the studies that have explored the applicability of personalized medicine to ILDs have been conducted in patients with IPF. Such studies have suggested the existence of several distinct disease subgroups defined by similar genetic profiles, molecular pathways, exposures and individual lifestyles. Personalized medicine in hypersensitivity pneumonitis is in its infancy. The development and applicability of personalized medicine to sarcoidosis, on the other hand, remains problematic for several reasons, including the lack of a diagnostic gold standard, the highly variable and unpredictable disease course, particularly across patients of different ethnicities, the poor correlation between disease activity and disease severity and the lack of a validated management algorithm.

Summary: A number of distinct patient subgroups have been identified in ILDs. Although available data need to be validated longitudinally, the possibility to study homogeneous groups of patients may allow prediction of disease behavior and response to treatment with dramatic clinical implications.
1078-1641
231-236
Spagnolo, Paolo
d0878a65-d386-401c-bf59-95ebddb3cfca
Oldham, Justin
3e231fa9-cdc9-44e1-b76a-a91185de011f
Jones, Mark
a6fd492e-058e-4e84-a486-34c6035429c1
Lee, Joyce
334c9d4e-3c2a-41f5-badd-5d00fabf0593
Spagnolo, Paolo
d0878a65-d386-401c-bf59-95ebddb3cfca
Oldham, Justin
3e231fa9-cdc9-44e1-b76a-a91185de011f
Jones, Mark
a6fd492e-058e-4e84-a486-34c6035429c1
Lee, Joyce
334c9d4e-3c2a-41f5-badd-5d00fabf0593

Spagnolo, Paolo, Oldham, Justin, Jones, Mark and Lee, Joyce (2017) Personalized medicine in interstitial lung diseases. Current Opinion in Pulmonary Medicine, 23 (3), 231-236. (doi:10.1097/MCP.0000000000000370).

Record type: Review

Abstract



Purpose of review: A number of recent studies have explored the possibility to apply personalized medicine to interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), the most common and deadly of the idiopathic interstitial pneumonias. In our review, we summarize and discuss the most recent literature on personalized medicine in IPF as well as hypersensitivity pneumonitis and sarcoidosis, with emphasis on patient subgroups for which a personalized approach to disease prognostication and management may become a reality in the near future.

Recent findings: Most of the studies that have explored the applicability of personalized medicine to ILDs have been conducted in patients with IPF. Such studies have suggested the existence of several distinct disease subgroups defined by similar genetic profiles, molecular pathways, exposures and individual lifestyles. Personalized medicine in hypersensitivity pneumonitis is in its infancy. The development and applicability of personalized medicine to sarcoidosis, on the other hand, remains problematic for several reasons, including the lack of a diagnostic gold standard, the highly variable and unpredictable disease course, particularly across patients of different ethnicities, the poor correlation between disease activity and disease severity and the lack of a validated management algorithm.

Summary: A number of distinct patient subgroups have been identified in ILDs. Although available data need to be validated longitudinally, the possibility to study homogeneous groups of patients may allow prediction of disease behavior and response to treatment with dramatic clinical implications.

Text
Accepted - Accepted Manuscript
Download (193kB)

More information

Accepted/In Press date: 15 February 2017
e-pub ahead of print date: 22 February 2017
Published date: May 2017
Organisations: Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 407835
URI: https://eprints.soton.ac.uk/id/eprint/407835
ISSN: 1078-1641
PURE UUID: a986f45e-2b64-4534-bb2f-a02d1e583de9

Catalogue record

Date deposited: 26 Apr 2017 01:15
Last modified: 10 Dec 2019 06:06

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×